key: cord-0807389-4bo9dc7b
authors: Dou, Qingyu; Wei, Xin; Zhou, Kehua; Shujuan,; Jia, Peng
title: Cardiovascular manifestations and mechanisms in patients with COVID-19
date: 2020-10-16
journal: Trends Endocrinol Metab
DOI: 10.1016/j.tem.2020.10.001
sha: 7dda419123fca85659e6d89e82a2c29a55a2a54f
doc_id: 807389
cord_uid: 4bo9dc7b

COVID-19 patients with preexisting cardiovascular diseases or with cardiovascular complications have showed a higher risk of mortality. The main cardiovascular complications of COVID-19 include acute cardiac injury, acute myocardial infarction, myocarditis, arrhythmia, heart failure, shock, and venous thromboembolism/pulmonary embolism. COVID-19 could cause cardiovascular complications or deterioration of coexisting cardiovascular diseases through direct or indirect mechanisms, including viral toxicity, dysregulation of the renin–angiotensin–aldosterone system, endothelial cell damage and thromboinflammation, cytokine storm, and demand-supply mismatch of oxygen. This study systematically reviews cardiovascular manifestations, histopathology, and mechanisms of COVID-19, to help formulate future research goals and facilitate the development of therapeutic management strategies.

Acute cardiac injury is defined as a rise of cardiac troponin values, with or without ejection fraction decline and electrocardiographic abnormalities. The prevalence of acute cardiac injury among COVID-19 patients was 10-23% [9] [10] [11] [12] , with a higher frequency in Intensive Care Unit (ICU) patients (22. 2% v.s. 2.0%) [9] and non-survivors (59.0% v.s. 1.0%) [11] . Patients with acute cardiac injury were associated with more severe illnesses, including higher C-reactive protein (CRP), N-terminal pro-b-type natriuretic peptide (NT-proBNP), and creatinine levels, as well as more multiple mottling and ground-glass opacity, and were more susceptible to noninvasive or invasive ventilation. Acute cardiac injury was also associated with cardiac dysfunction and malignant arrhythmias [13] . Patients with acute cardiac injury exhibited a significant higher risk of mortality both during the time from symptom onset (HR=4.26, 95% CI [1. 92-9.49] ) and from admission to end point (HR=3.41, 95% CI [1.62-7.16 ]) [14] . Greater magnitude and frequency of cardiac troponin elevation were also associated with higher mortality [14] .

COVID-19 patients with previous CVD were more prone to suffer acute cardiac injury.

Compared to the patients without cardiac injury, there was a higher prevalence of coronary heart diseases (29.3% v.s. 6.0%) and hypertension (59.8% v.s. 23 .4%) in those with cardiac injury [14] . Moreover, once infected by SARS-CoV-2, patients with CVD comorbidities usually had worse cardiac reserve and poorer tolerance to hypoxia, and were more likely to deteriorate cardiac insufficiency (e.g., heart failure, malignant arrhythmia and shock).

Respiratory viruses, such as SARS and influenza, are associated with acute myocardial infarction (AMI) by increasing the risk of coronary plaque rupture [15, 16] . The incidence ratio for patients to develop AMI during one week after influenza diagnosis, as compared to one year after influenza diagnosis, is 6.05 (95% CI [3.86 to 9.50]) [17] . AMI can occur in COVID-19 patients, but the incidence of such events is unknown. Newly diagnosed AMI was reported in 5.3% of cases in an electrocardiographic study of COVID-19 [18] , and 2.9 % in another echocardiography study [19] . ST-elevation myocardial infarction (STEMI) can present as the initial clinical manifestation of COVID-19 [20] . There were 33.3-39.3% of patients with COVID-19 and STEMI absent of obstructive coronary artery disease [20] [21].This phenomenon indicated COVID-19 itself may be connected with endothelial dysfunction as well as hypercoagulable state. Meanwhile, COVID-19 has also profoundly reshaped the pathway of usual patients with AMI. The hospitalization rates of AMI reduced in the early duration of COVID-19 and after 5 weeks mildly recovered with raised in-hospital mortality in the US [22] . A great deal of patients with AMI, perhaps due to fear of contracting SARS-CoV-2, kept away from hospitalization at the time of the COVID-19 pandemic and resulted in the delay and aggravation of AMI. Further studies are required to discover the impact of COVID-19 on AMI.

Myocarditis is defined as myocardial damages caused by direct viral attack on the heart. Five (7%) of 68 patients with myocardial damages died of circulatory failure [23] , and a patient presented as the 3 rd degree atrioventricular block was reported as myocarditis [18] in the early period of COVID-19. There are a few COVID-19 related myocarditis cases confirmed by cardiac MRI [24] [25] [26] [27] . However, the proof of viral entry into cardiomyocytes is fairly restricted. Although endomyocardial biopsy found evidence of lymphocytic inflammatory infiltrates in the myocardium, SARS-CoV-2 particles were found only in interstitial cells of the myocardium [28] . Another COVID-19 case demonstrated lymphocytic myocarditis without SARS-CoV-2 within the myocardium [29] . The immune-mediated hyperinflammation may act a more significant part than viral replication or toxicity involved in the pathophysiology of acute myocarditis about COVID-19. Pericardial involvement with cardiac tamponade has also been reported [30, 31] .

Arrhythmias took place in 16.7% amongst 138 hospitalized COVID-19 patients, with a greater proportion in ICU patients than in non-ICU patients (44.4% v.s. 6.9%, p<0.001) [9] .

COVID-19 presented with various arrhythmias has a strong association with the severity of the disease. For example, compared with the patients in the non-ICU group, the proportion of abnormal Q-wave in ECG from the patients in ICU group increased (33.3% v.s. 3.9%, p=0.006) [18] . The presence of ventricular arrhythmias is higher among patients with acute cardiac injury than patients without acute cardiac injury (17.3% v.s. 1.5%, p<0.001) [13] .

Atrial arrhythmias were more common among patients who required mechanical ventilation than among those who did not (17.7% v.s. 1.9%) [32] . Prolonged corrected QT (>500 ms)

found in 6% of 4,250 patients with COVID-19 in a New York cohort should not be ignored [26] . In 136 COVID-19 patients who experienced in-hospital cardiac arrest, asystole as the most common initial rhythm happened in 89.7% of cases, whereas a shockable rhythm was found in just 5.9% of patients [33] . Sudden cardiac death has also occurred in COVID-19 J o u r n a l P r e -p r o o f patients with mild symptoms at the beginning who were later discovered dead at home [34] .

In contrast to the decline of patients with AMI in the early COVID-19 pandemic, out-of-hospital cardiac arrest reported an increase of 58% during the 40 days of the COVID-19 outbreak compared to the same period in 2019. COVID-19 or other untreated diseases such as AMI with patients' unwillingness to look for treatment may contribute to the phenomenon [35] . Arrhythmias in the population with COVID-19 developed secondary to hypoxemia, metabolic derangements, electrolyte disorder, systemic inflammation, electrical instability with adrenergic stress, AMI or myocarditis, and treatment with QT prolonging drugs.

Heart failure was observed in 23% of patients with COVID-19 and the proportion of heart failure was higher in non-survivors than survivors (52% v.s. 12%, p<0.001) [11, 36] . In accordance with troponin, the rise of BNP/NT-proBNP is related to poor prognosis among individuals with COVID-19 [37] . In seriously ill patients with COVID-19, biventricular failure accounted for 7% to 33% [37, 38] . Studies have also reported separated right ventricular failure with or without PE [39, 40] . A few case reports have revealed the novel connection between stress cardiomyopathy (takotsubo syndrome) and COVID-19 [41] [42] [43] .

The incidence of stress cardiomyopathy (7.8%) increased significantly during the COVID-19 outbreak when compared with pre-pandemic periods (1.5-1.8%) [44] . COVID-19 produced financial, social, and mental pressure to provoke the occurrence of stress cardiomyopathy.

The microvascular disorder, cytokine storm, and sympathetic stress may participate in the pathophysiology of stress cardiomyopathy.

As an end-stage manifestation of CVD, heart failure may be the long-term consequence of cardiac infection by SARS-CoV-2. In a recent cohort study that included 100 patients recovered from COVID-19, cardiac involvement in 78 patients and continuous myocardial inflammation in 60 patients were recognized by cardiac MRI, regardless of preexisting CVD or the severity of the illness [45] . making, particularly when requiring mechanical respiratory, and circulatory assistance with extracorporeal membranous oxygenation (ECMO), since this may influence the selection of devices (venovenous v.s. venoarterial) [46] .

In the later phase of COVID-19 pandemic, healthy children displaying atypical Kawasaki disease (KD) have been given much attention in the US and Europe [47, 48] . This syndrome was named as pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). It manifested as consistent fever, evidence of inflammation (neutrophilia, raised CRP, and lymphopenia), and single or multiorgan dysfunction (shock, cardiac, respiratory, kidney, gastrointestinal, or neurological disorder) under the condition of existing or previous infection with SARS-CoV-2. Comparison of PIMS-TS with KD or KD shock syndrome showed older age and greater elevation of inflammatory markers such as CRP [49] . Untreated KD can lead to coronary aneurysms in 25% of patients.

SARS-CoV-2-induced immune dysregulation may give the impetus to the onset of PIMS-TS, since the majority of children with PIMS-TS were detected positive for antibodies of SARS-CoV-2 but negative for nucleic acids [50] .

COVID-19 has been associated with proinflammatory and prothrombotic circumstances which can result in thromboembolic events [51, 52] . In fact, higher markers of thrombosis have been associated with worse clinical outcomes. In a Chinese multicenter study, elevated D-dimer levels (> 1 g/L) were independent predictors of in-hospital death [11] . Furthermore, 71 .4% of patients who died were diagnosed as disseminated intravascular coagulation [53] . A study reported a high VTE incidence of 69% in ICU patients [54] . However, other centers have reported lower VTE rates (22.2%) [55] . Despite prophylactic anticoagulation, 31% of patients with COVID-19 still developed VTE [56] and 16.7% of patients were diagnosed as PE [57] . PE were more likely to occur in ARDS patients with COVID-19 compared with non-ARDS individuals (11.7 v.s. 2.1%, p<0.008) [57] . Another study disclosed a cumulative incidence of PE of 20.4% (95% CI [13.1%-28.7%]) in critical COVID-19 patients, notably higher than that of patients in the identical ICU at the same time in 2019 [58] .

The pathology of COVID-19 results from both direct and indirect injuries. Table   2 ). The various possible mechanisms that may contribute to the pathogenesis of cardiovascular complications of COVID-19 are discussed at gross, cellular, and molecular levels (Figure 1) .

Angiotensin-converting enzyme 2 (ACE2) existed in the vascular system (as endothelial cells, vascular smooth muscle cells, and migratory angiogenic cells) and the heart (as cardiofbroblasts, cardiomyocytes, endothelial cells, pericytes, as well as epicardial adipose cells) [59] . ACE2 functions as an entry receptor by binding to the spike protein of SARS-CoV and SARS-CoV-2. In addition, completion of cell entry necessitates priming of the spike subunit by the cellular serine protease TMPRSS2 (transmembrane protease serine 2) or other proteases (cathepsin L, cathepsin B, factor X, trypsin, elastase, and furin) [60] . The increased transmissibility of SARS-CoV-2 could be interpreted by greater affinity of binding of SARS-CoV-2 to ACE2 than of SARS-CoV to ACE2 [61] . Furthermore, patients with previous CVDs were associated with more severe COVID-19, possibly because they had higher plasma levels of ACE2 [62] . Nevertheless, compared to the lung, the human heart had been discovered with higher expression of ACE2 and with much lower content of TMPRSS2.

The susceptibility of SARS-CoV-2 infection of the heart was diminished by a low portion of ACE2+/TMPRSS2+ cells to some extent. Other S-protein priming proteases considerably expressed in the human heart, cathepsin L and furin, may increase heart vulnerability to SARS-CoV-2 [63] .

ACE2 converts angiotensin II (Ang II) to Ang-(1-7), and the ACE2/Ang-(1-7)/Mas axis combats the adverse impacts of the RAAS, which takes essential responsibility in preserving the physiological and pathophysiological equilibrium of the body. The entrance of SARS-CoV-2 into cells is assisted by the interplay between S-proteins with extracellular domains of ACE2 protein, with downregulation of surface ACE2 expression subsequently.

Then, Ang-II /angiotensin 1 receptor (AT1R) activity increased at the expense of ACE2/Ang 1-7/Mas axis, bringing about comprehensive negative consequences, including aldosterone secretin, fibrosis, pro-inflammation, hypertrophy, vasoconstriction, enhanced reactive oxygen species and vascular permeability, cardiac remolding, gut dysbiosis and multiple organ dysfunction syndrome (MODS) in COVID-19 [59] [64] . ACE2 exerts multiple protective J o u r n a l P r e -p r o o f effects in numerous organs and various diseases, and genetic ACE2 deficiency is associated with adverse results. ACE2 knockout mice displays with myocardial hypertrophy and interstitial fibrosis and aggravates heart dysfunction [65] . ACE2 deficiency substantially worsened the pathogenesis in H5N1 infected mice, and suppression of AT1 relieved the severity of lung damage [66] . ACE2 could also stimulate insulin secretion and lower insulin resistance [67] . The evidence showed downregulation of ACE2 expression in myocardial cells in both SARS-CoV-infected mice and humans [68] . There is also a positive correlation between elevated circulating Ang II levels in COVID-19 patients and lung injury or viral load.

In short, a direct link between tissue ACE2 downregulation and upregulation of Ang II was partially responsible for the development of cardiovascular complications or multiorgan failure from SARS-CoV-2 infection [69, 70].

The direct invasion of endothelial cells by SARS-CoV-2 infection and the indirect generation of inflammation and prothrombotic conditions in vasculopathy took part in the pathophysiological mechanisms of COVID-19 [71] [72] [73] . Both venous and arterial endothelium of certain organs have identified ACE2 expression [71] . Meanwhile, histopathological studies have discovered microscopic evidence of SARS-CoV-2 viral particles in endothelial cells of the kidneys, as well as obvious endotheliitis featured by activated neutrophils and macrophages in numerous organs including the lung, intestine and heart [73] . Von Willebrand factor (VWF), a circulating adhesive glycoprotein associated with endothelial dysfunction, significantly elevated in COVID-19 patients compared to normal individuals [74] . VWF can trigger platelets to gather and engage in blood coagulation as a carrier of coagulation factor VIII [75] . Platelet-neutrophil interaction and activation of macrophages in this condition can further promote a variety of proinflammatory responses, such as cytokine storm and the formation of neutrophil extracellular traps (NETs) [76] . NETs destruct the endothelium and stimulate both extrinsic and intrinsic coagulation pathways resulting in microthrombus formation and microvascular dysfunction. NETs were measured at higher levels in hospitalized patients with COVID-19, positively correlating with disease severity [77] .

Inhibiting NETs may be a therapeutic target to ameliorate NET-mediated thrombotic tissue damage associated with COVID-19 [78] .

Dysregulated immune response and following cytokine storm characterize the presentation of severe COVID-19. Previous studies with human coronaviruses have exhibited fast viral replication, interference of interferon signaling, and recruitment of inflammatory cells (neutrophils and monocyte-macrophages) as mediators of hyperinflammation [79] .

Immunity measurements, such as white blood cells, neutrophils and categories of lymphocytes and inflammation parameters (CRP and procalcitonin), were independently related to acute cardiac injury in patients with COVID-19 [80] . Subsequent cytokine storm, characterized by a sharp rise in the level of a large number of pro-inflammatory cytokines triggered by infection, has been observed in H1N1 [81] , SARS [79, 82] , MERS [79, 82] and is an important cause of death ( Table 3) . A comprehensive evaluation of the transcriptional response to SARS-CoV-2 disclosed a special and improper inflammatory reaction specified by decreased levels of type I and III interferons combined with increased chemokines and high levels of IL-6. Reduced innate antiviral defenses and raised pro-inflammatory responses contribute to COVID-19 [83] . Zhou's study revealed after SARS-CoV-2 infection, pathogenic T helper 1 cells and inflammatory CD14+CD16+ monocytes incited a high amount of granulocyte macrophage colony-stimulating factor and IL-6 expression [84] . Higher levels of IL-6 in the serum have also been linked to a worse prognosis [37, [85] [86] [87] and found to correlate with fibrinogen levels in patients with COVID-19 [88] . IL-6 can activate coagulation, induce thrombosis [89], inhibit heart function [90] , and cause endothelial dysfunction, leading to vascular leakage, tissue ischemia and hypoxia, and thus to a drop in blood pressure, disseminated intravascular coagulation (DIC) and MODS [91] .

Hypoxemia is the main manifestation of COVID-19, which results in a relative or absolute insufficiency in oxygen supply to organs with a high demand for oxygen and energy; especially in the heart [92] . It is considered that the imbalance of oxygen supply and demand caused by cytokine storm as well as endothelial dysfunction, without acute atherothrombotic plaque disruption, similar to the pathophysiology of type 2 myocardial infarction, leads to cardiac injury in COVID-19 [93, 94] . The mechanism of type 2 MI is the potential mechanism of cardiac damage in acute infection [93] . On one hand, cytokine storm caused the release of IL-6 and catecholamines, which increased the core body temperature and heart rate, and increased cardiac oxygen consumption. On the other hand, endothelial dysfunction and cytokine storm affected the cardiac microenvironment, causing pathological changes, such as coronary artery spasm and thrombosis, all of which lead to a decreased blood supply of the J o u r n a l P r e -p r o o f coronary artery. A reflexive elevated heart rate will further decrease myocardial perfusion due to a decreased filling time. Severe hypoxemia, hypotension, and anemia in critically ill patients with COVID-19 further aggravate the oxygen supply. A combination of these factors causes the mismatch between oxygen demand and supply, leading to acute cardiac damage.

Indeed, compared to type 1 MI caused by plaque rupture with thrombus formation, patients who suffer from type 2 MI have higher mortality rates, which may be partially interpreted by a higher burden of acute and chronic multimorbidity conditions in the population with type 2 MI [95] . Given the age and comorbidity of hospitalized patients with severe COVID-19, it is reasonable to speculate that the presence of type 2 MI in these patients is likely an indicator of more severe diseases and worse prognosis of COVID-19 [14] .

The COVID-19 pandemic stands for the most significant public health crisis of the century. Because of the significant association with increased mortality, CVDs is an obvious and important comorbidity of COVID-19 and other respiratory viruses, and it is among the leading cause of mortality among COVID-19 patients [96] . Due to quarantine restrictions, the COVID-19 pandemic served as a major cause of stress for our public emerging systems and medical health systems, especially in the main epidemic areas of COVID-19 and low-income and middle-income countries (e.g., Brazil, India and South Africa). This may delay medical therapeutic approaches of acute cardiovascular emergencies such as a stroke or an AMI [97] . Therefore, it is necessary to heighten awareness of, and capabilities for, self-protection among individuals with CVDs and improve treatment efficiency for COVID-19 patients with comorbidities to reduce mortality. Additionally, telemedicine is considered as another potential solution for healthcare access challenges in rural communities and routine follow-up visit of individuals with CVDs [98] .

However, there are currently no therapeutic drugs available to treat COVID-19. Therefore, Influenza vaccine can reduce the risk of cardiovascular events by 26%-35% and all-cause mortality by 43% in the general adult population [99, 100] . For high-risk patients with a history of recent AMI, influenza vaccine bought more benefits by reducing the cardiovascular events risk of 55% [100] . Therefore, the vaccination for COVID-19, if limited, should be prioritized to patients with CVDs as one of the important secondary preventions, especially those with cardiometabolic disorders, to continuously reduce the risk of cardiovascular events. 

COVID-19 Dashboard by the center for systems science and engineering

Coronaviruses and the cardiovascular system: acute and long-term implications

Report of the WHO-China Joint Mission on Coronavirus Disease

Hypertension is a risk factor for adverse outcomes in patients with coronavirus disease 2019: a cohort study

The prevalence of cardiovascular comorbidities in COVID-19, SARS and MERS: pooled analysis of published data

Epidemiological and Clinical Characteristics of Coronavirus Disease

Preexisting Comorbidities Predicting COVID-19 and Mortality in the UK Biobank Community Cohort

Predictors of Adverse Prognosis in Covid-19: A Systematic Review and Meta-analysis

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Prognostic impact of high sensitive Troponin T in patients with influenza virus infection: A retrospective analysis

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection

Mar) Electrocardiogram abnormalities in patients with COVID-19

Global evaluation of echocardiography in patients with COVID-19

ST-Elevation Myocardial Infarction in Patients With COVID-19: Clinical and Angiographic Outcomes

ST-Segment Elevation in Patients with Covid-19 -A Case Series

Case Rates, Treatment Approaches, and Outcomes in Acute Myocardial Infarction During the Coronavirus Disease

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

COVID-19-related myocarditis in a 21-year-old female patient

Myocarditis in a 16-year-old boy positive for SARS-CoV-2

Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes

Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19)

Myocardial localization of coronavirus in COVID-19 cardiogenic shock

Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection

Mar 30) Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19

Cardiac Tamponade Secondary to COVID-19

Cardiac and arrhythmic complications in patients with COVID-19

Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

COVID-19 complicated by Acute Pulmonary Embolism and Right-Sided Heart Failure

Acute Cor Pulmonale in Critically Ill Patients with Covid-19

Typical takotsubo syndrome triggered by SARS-CoV-2 infection

A case of Takotsubo cardiomyopathy with COVID 19

Takotsubo cardiomyopathy triggered by SARS-CoV-2 infection in a critically ill patient

Incidence of Stress Cardiomyopathy During the Coronavirus Disease

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation

Hyperinflammatory shock in children during COVID-19 pandemic

Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Extrapulmonary manifestations of COVID-19

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Thrombotic events in SARS-CoV-2 patients: an urgent call for ultrasound screening

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence

Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig

Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling

Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart

Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases

Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction

Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections

The ACE2/Angiotensin

SARScoronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

COVID-19: the vasculature unleashed

Endothelial cell infection and endotheliitis in COVID-19

Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis

A biophysical view on von Willebrand factor activation

Neutrophils and Neutrophil Extracellular Traps Drive Necroinflammation in COVID-19

Neutrophil extracellular traps in COVID-19

Neutrophil Extracellular Traps (NETs) Contribute to Immunothrombosis in COVID-19 Acute Respiratory Distress Syndrome

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

SARS-CoV-2-Induced Immune Dysregulation and Myocardial Injury Risk in China: Insights From the ERS-COVID-19 Study

Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza

Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Heart injury signs are associated with higher and earlier mortality in coronavirus disease

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock

Immunotherapeutic implications of IL-6 blockade for cytokine storm

Towards precision management of cardiovascular patients with COVID-19 to reduce mortality

Acute Infection and Myocardial Infarction

Type 2 Myocardial Infarction: JACC Review Topic of the Week

Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury

Clinical characteristics and risk factors for mortality among inpatients with COVID-19 in Wuhan

Mar 27) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

Telemedicine and the Forgotten America

Effects of influenza vaccination on the risk of cardiovascular and respiratory diseases and all-cause mortality

Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis

Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1)

The emerging influenza pandemic: estimating the case fatality ratio

Clinical characteristics of fatalities due to influenza A (H1N1) virus in Mexico

Seasonal Influenza Infections and Cardiovascular Disease Mortality

MERS transmission and risk factors: a systematic review

Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk

East respiratory syndrome

Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia

Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis

Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome

Effects of Underlying Disease on the Prognosis in Patients with Severe Acute Respiratory Syndrome

Analysis of the relative factors associated with dealth in adult SARS patients

Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies

COVID-19 Autopsies

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities

Fatal Eosinophilic Myocarditis in a Healthy 17-Year-Old Male with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2c)

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Unexpected Features of Cardiac Pathology in COVID-19 Infection

Case 23-2020: A 76-Year-Old Woman Who Died from Covid-19

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive

Immunothrombotic Dysregulation in COVID-19 Pneumonia is Associated with Respiratory Failure and Coagulopathy

Multiorgan and Renal Tropism of SARS-CoV-2

Postmortem Examination of Patients With COVID-19

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy

Late histological findings in symptomatic COVID-19 patients: A case report

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv

CI: confidence interval; COVID-19: coronavirus disease 2019; MERS: Middle East respiratory syndrome; OR: odds ratio; SARS: severe acute respiratory

IL-17, TNF-α, IL-15 and IL-12p70

SARS IL-1β, IL-6, IL-12, IFN-γ, IP-10 and MCP-1

COVID-19 GM-CSF

COVID-19: coronavirus disease 2019; GM-CSF: human granulocyte-macrophage colony stimulating factor; IL: Interleukin; IP: Interferon-inducible protein

MCP: monogyte chemoattractant protein; MERS: Middle East respiratory syndrome; MIP-1A: macrophage inflammatory protein-1 alpha; SARS: severe acute respiratory syndrome

Buja [121] USA 3 · Lymphocytic pericarditis · Multifocal acute injury of cardiomyocytes without inflammatory cellular infiltratesOne case with fibrin-rich thrombi in renal capillaries and small vessels Craver [122] USA 1 (17) Enlarged flabby heart with eosinophilic myocarditis NA Fox [